Home Cart Sign in  
Chemical Structure| 479-98-1 Chemical Structure| 479-98-1

Structure of Aucubin
CAS No.: 479-98-1

Chemical Structure| 479-98-1

*Storage: {[sel_prStorage]}

*Shipping: {[sel_prShipping]}

,{[proInfo.pro_purity]}

Aucubin is an iridoid glycoside with a wide range of biological activities, including anti-inflammatory, anti-microbial, anti-algesic as well as anti-tumor activities.

Synonyms: Rhinanthin

4.5 *For Research Use Only !

{[proInfo.pro_purity]}
Cat. No.: {[proInfo.prAm]} Purity: {[proInfo.pro_purity]}

Change View

Size Price VIP Price

US Stock

Global Stock

In Stock
{[ item.pr_size ]} Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate,item.pr_is_large_size_no_price, item.vip_usd) ]}

US Stock: ship in 0-1 business day
Global Stock: ship in 5-7 days

  • {[ item.pr_size ]}

In Stock

- +

Please Login or Create an Account to: See VIP prices and availability

US Stock: ship in 0-1 business day
Global Stock: ship in 2 weeks

  • 1-2 Day Shipping
  • High Quality
  • Technical Support
Product Citations

Alternative Products

Product Details of Aucubin

CAS No. :479-98-1
Formula : C15H22O9
M.W : 346.33
SMILES Code : O[C@H]([C@@H](O)[C@@H]1O)[C@](O[C@@H]1CO)([H])O[C@H](OC=C2)[C@@]3([H])[C@]2([H])[C@H](O)C=C3CO
Synonyms :
Rhinanthin
MDL No. :MFCD00136026
InChI Key :RJWJHRPNHPHBRN-FKVJWERZSA-N
Pubchem ID :91458

Safety of Aucubin

GHS Pictogram:
Signal Word:Warning
Hazard Statements:H302
Precautionary Statements:P264-P270-P301+P312+P330-P501

Isoform Comparison

Biological Activity

In Vitro:

Cell Line
Concentration Treated Time Description References
primary cortical neurons 50 μg/ml, 100 μg/ml, 200 μg/ml 12 h To evaluate the protective effects of Aucubin against H2O2-induced oxidative stress. Results showed that Aucubin significantly enhanced the translocation of Nrf2 into the nucleus, activated antioxidant enzymes, suppressed excessive generation of ROS, and reduced cell apoptosis. J Neuroinflammation. 2020 Jun 15;17(1):188
hBM-MSCs 0, 0.01, 0.1, 1 μM 3, 7 days To evaluate the effect of Aucubin on osteogenic differentiation of hBM-MSCs. The results showed that Aucubin significantly increased the expression of osteogenesis-related genes and promoted early and late mineralization. Stem Cell Res Ther. 2022 Aug 19;13(1):424
hBM-MSCs 0, 0.01, 0.1, 1 μM 1, 3, 5, 7 days To evaluate the effect of Aucubin on the viability and proliferation of hBM-MSCs. The results showed that different concentrations of Aucubin did not have a significant impact on the viability and proliferation of hBM-MSCs at different time nodes. Stem Cell Res Ther. 2022 Aug 19;13(1):424
neonatal rat cardiomyocytes 1, 3, 10, 25 and 50 μM 24 h To evaluate the effect of Aucubin on cardiomyocyte hypertrophy. Results showed that Aucubin at 50 μM significantly reduced cell surface area and mRNA expression levels of ANP and β-MHC. Br J Pharmacol. 2018 May;175(9):1548-1566
H9c2 cardiomyocytes 1, 3, 10, 25 and 50 μM 24 h To evaluate the effect of Aucubin on cardiomyocyte hypertrophy. Results showed that Aucubin at higher concentrations (10 and 50 μM) significantly reduced cell surface area and mRNA expression levels of ANP and β-MHC. Br J Pharmacol. 2018 May;175(9):1548-1566
rat primary chondrocytes 50 μM 24 h To assess the inhibitory effect of Aucubin on IL-1β-induced chondrocyte apoptosis, results showed Aucubin significantly reduced apoptosis rate. Drug Des Devel Ther. 2019 Oct 9;13:3529-3538
rat primary chondrocytes 1, 10, 20, 50 μM 24 and 48 h To evaluate the protective effect of Aucubin on IL-1β-induced cytotoxicity in chondrocytes, results showed Aucubin significantly reversed IL-1β-induced cytotoxicity. Drug Des Devel Ther. 2019 Oct 9;13:3529-3538
PC12 cells 10 µM, 500 µM, 5 mM 24 h To evaluate the effect of AU on gene expression in PC12 cells, results showed significant downregulation of CXCL10 and BTN3A2 expression Front Immunol. 2023 Feb 23;14:1007624
HFLS cells 16 µM 24 h To evaluate the effect of AU on gene expression in HFLS cells, results showed no significant changes in the expression levels of the six diagnostic markers, but significant downregulation of bIII-tubulin gene expression Front Immunol. 2023 Feb 23;14:1007624
PC12 cells 0-5 mM 24 h To evaluate the effect of AU on cell proliferation ability, results showed AU significantly increased the proliferation of PC12 cells Front Immunol. 2023 Feb 23;14:1007624
su5416-injured human umbilical vein endothelial cells (HUVECs) 5–20 μM 48 h To evaluate the effect of Aucubin on the proliferation of su5416-injured HUVECs, results showed that 5–20 μM aucubin significantly increased the cell viability of su5416-injured HUVECs. Chin Med. 2023 Aug 29;18(1):108
Human umbilical vein endothelial cells (HUVECs) 6.25–100 μM 48 h To evaluate the effect of Aucubin on the proliferation of HUVECs, results showed that 25–100 μM aucubin increased the cell viability of HUVECs. Chin Med. 2023 Aug 29;18(1):108

In Vivo:

Species
Animal Model
Administration Dosage Frequency Description References
C57BL/6 mice Weight-drop induced traumatic brain injury model Intraperitoneal injection 20 mg/kg or 40 mg/kg Administered at 30 min, 12 h, 24 h, and 48 h post-injury To evaluate the protective effects of Aucubin on traumatic brain injury. Results showed that Aucubin significantly attenuated brain edema, histological damages, and improved neurological and cognitive deficits. Additionally, Aucubin significantly suppressed HMGB1-mediated aseptic inflammation. Nrf2 knockdown blunted the antioxidant and anti-inflammatory neuroprotective effects of Aucubin. J Neuroinflammation. 2020 Jun 15;17(1):188
C57BL/6 male mice Destabilization of the medial meniscus (DMM) model Oral gavage 50 mg/kg Once daily for 8 weeks To evaluate the protective effect of Aucubin on OA progression in DMM mouse model, results showed Aucubin significantly attenuated proteoglycan loss and cartilage erosion. Drug Des Devel Ther. 2019 Oct 9;13:3529-3538
Gerbils Forebrain ischemia-reperfusion injury (fIRI) model Intraperitoneal injection 1, 5, and 10 mg/kg Once daily for seven days To evaluate the neuroprotective effects of Aucubin against forebrain ischemia-reperfusion injury. Results showed that pretreatment with 10 mg/kg of Aucubin significantly improved short-term memory function and protected hippocampal CA1 pyramidal cells from ischemia-reperfusion injury. Antioxidants (Basel). 2023 May 11;12(5):1082
Transgenic medaka (Oryzias latipes) RANKL-induced osteoporosis model Immersion 25 and 50 μM Once daily for 5 days To evaluate the effect of Aucubin on RANKL-induced osteoporosis in medaka, results showed that 25 and 50 μM aucubin reduced the resorption of the mineralized bone matrix and centra degradation. Chin Med. 2023 Aug 29;18(1):108

Protocol

Bio Calculators
Preparing Stock Solutions 1mg 5mg 10mg

1 mM

5 mM

10 mM

2.89mL

0.58mL

0.29mL

14.44mL

2.89mL

1.44mL

28.87mL

5.77mL

2.89mL

Dissolving Methods
Please choose the appropriate dissolution scheme according to your animal administration guide.For the following dissolution schemes, clear stock solution should be prepared according to in vitro experiments, and then cosolvent should be added in turn:

in order to ensure the reliability of the experimental results, the clarified stock solution can be properly preserved according to the storage conditions; The working fluid for in vivo experiment is recommended to be prepared now and used on the same day;

The percentage shown in front of the following solvent refers to the volume ratio of the solvent in the final solution; If precipitation or precipitation occurs in the preparation process, it can be assisted by heating and/or ultrasound.
Protocol 1
Protocol 2

References

 

Historical Records

Categories